Phoenix PK/PD Modeling and Simulation Software Certara’s Phoenix® platform is the leading PK/PD modeling and simulation software used worldwide by more than 6,000 researchers at biopharmaceutical companies, academic institutions, and global regulatory agencies, including eleven divisions of the US FDA. Phoenix includes WinNonlin™, the industry standard for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and toxicokinetic […]
Read More
Topics:
In the ongoing commitment to education and coinciding with the launch of Phoenix 8.1, Certara has introduced a new certification program available through Certara University. The new online accreditation program validates the scientists’ PK/PD data analysis skills using Certara software such as Phoenix WinNonlin and expands their professional reach. I caught up with Ana Henry, […]
Read More
Topics:
Clinical Pharmacology Strategy, PBPK Modeling & Simulation, PK/PD Modeling & Simulation
A Compendium of Insightful Information for Our Phoenix Community, Vol. 4 Welcome to The Phoenix® Reporter. In this e-newsletter, we will share informative educational content along with practical, implementable resources with our Phoenix user community. This issue provides an overview of the new features and enhancements in Phoenix 8.1, the newest version of our PK/PD software: What’s New in […]
Read More
Topics:
Phoenix 8.1, the newest version of Certara’s innovative PK/PD modeling and simulation software used globally by researchers and drug developers in pharma, academia, and regulatory agencies, will be available on June 15, 2018. Major enhancements were introduced in the Phoenix workbench last year. And as an ongoing commitment to support compliance and efficiency, many features […]
Read More
Topics:
PK/PD Modeling & Simulation
Phoenix PK/PD Modeling and Simulation Software Certara’s Phoenix platform is the leading PK/PD modeling and simulation software used worldwide by 6,000 researchers at biopharmaceutical companies, academic institutions, and global regulatory agencies, including eleven divisions of the US FDA. Phoenix extends the winning formula of WinNonlin by combining its trusted algorithms with built-in, easy-to-use graphical user […]
Read More
Topics:
Phoenix PK/PD Modeling and Simulation Software Certara’s Phoenix platform is the leading PK/PD modeling and simulation software used worldwide by 6,000 researchers at biopharmaceutical companies, academic institutions, and global regulatory agencies, including eleven divisions of the US FDA. Phoenix extends the winning formula of WinNonlin by combining its trusted algorithms with built-in, easy-to-use graphical user […]
Read More
Topics:
E-learning Courses: Training at Your Convenience Certara University has expanded its educational reach via the introduction of an e-learning platform. E-learning classes are now available in various topics such as Introduction to Phoenix Winnonlin, Population Modeling Using Phoenix NLME, Fundamentals of Pharmacokinetics, Non-compartmental Data Analysis, Introduction to Statistics with R, and many other courses. See […]
Read More
Topics:
Meet the Certara University Trainers Nathan Teuscher is a leader in the pharmaceutical industry as a scientist, consultant, and teacher. Nathan has been teaching and training for over 15 years in the pharmaceutical industry, providing lectures in general pharmacokinetics to non-scientists, and specialized training in population pharmacokinetics and drug development to industry experts. Nathan also […]
Read More
Topics:
Course Catalog Classroom Courses (100-CL) Introduction to Phoenix WinNonlin [2020] Cost – $1,500 (Academia $750) (100-CL,102-CL) [India] Introduction to Phoenix WinNonlin plus the IVIVC Toolkit [2020] Cost – $ 700 (Academia $ 500) [~50,300 INR (Academia ~36,000 INR)] (101-CL) Introduction to Population Modeling using Phoenix NLME [2020] Cost – $1,500 (Academia $750) (207-CL) Intermediate PK/PD Modeling using Phoenix […]
Read More
Topics:
Classroom Courses: Training in Group Settings Certara’s classroom trainings are offered by our scientific experts and leadership in variety of topics including: Population Modeling Methodology IVIVC Toolkit for Phoenix WinNonlin—In Vivo-In Vitro Correlations Intermediate PK/PD Modeling Methodology Variety of Simcyp Workshops Classroom trainings are offered around the globe and course schedules are posted on the Certara […]
Read More
Topics:
On-site Training: We’ll Come to You Certara University trainers deliver PK/PD modeling and simulation courses at your site! Certara’s on-site training is one of the most cost-effective ways to facilitate your organization’s learning and development goals. Choose from our standard curriculum or customize training to fit your organization’s needs with an expert on-site. We will […]
Read More
Topics:
A Compendium of Insightful Information for Our Phoenix Community June 2018 Welcome to The Phoenix® Reporter. In this e-newsletter, we will share informative educational content along with practical, implementable resources with our Phoenix user community. This issue provides an overview of the new features and enhancements in Phoenix 8.1, the newest version of our PK/PD software: What’s New […]
Read More
Topics:
Choosing the Right Software for PK/PD Analysis The methods used to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of a compound can be inherently complex and sophisticated. PK/PD analysis is a science that requires a mathematical and statistical background, combined with an understanding of biology, pharmacology, and physiology. PK/PD analysis guides critical decisions in drug […]
Read More
Topics:
About our Clinical Trial Outcomes Databases Our Clinical Trial Outcomes Databases form a quantitative framework to leverage valuable external data, providing key development insights to maximize the probability of success for a new drug. Comparative effectiveness Endpoint and subpopulation relationships Biomarker efficacy and safety outcome Trial design optimization Competitive analysis and commercial viability Gathering, formatting, […]
Read More
Topics:
Strategic Modeling and Simulation Services for Autoimmune Disorders Certara Strategic Consulting scientists have extensive experience in immunological disorders. We have also leveraged comparator data to support Phase 2b dose selection for the treatment of autoimmune disorders. Disease Areas Rheumatoid arthritis Psoriasis Crohn’s disease Systemic sclerosis Multiple sclerosis Clinical Trial Outcomes Databases We have developed an […]
Read More
Topics:
The Importance of Modeling & Simulation Education Certara University is dedicated to shaping the future of healthcare innovation through modeling and simulation education. Certara University provides modeling and simulation education, skills, and expertise in the global healthcare industry. We recognize that continuing education in both the theory and practice of modeling and simulation in drug […]
Read More
Topics:
Modeling and simulation was used to support the approval of a monoclonal antibody based on small clinical trials and evidence from a previous indication.
Read More
Topics:
Oncology: Strategic Modeling and Simulation Services Certara has extensive experience supporting oncology drug development. In addition, we have applied a range of modeling techniques to address critical decisions from pre-clinical to late stage clinical for antibodies, proteins and small molecules, such as C-QT modeling, metadata analysis, preclinical to Phase 2 PK and TK analysis, and […]
Read More
Topics:
Infectious Disease: Strategic Modeling and Simulation Services Drug development for infectious diseases faces unique challenges including compliance, viral dynamics, and drug resistance. Certara has extensive experience in infectious disease projects, including many HIV and HCV viral dynamics/kinetics modeling projects over the past decade, in all clinical development phases. We have covered critical issues in trial […]
Read More
Topics:
